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Abstract
The effects of tau hyperphosphorylation and aggregation on axonal transport were investigated in the optic nerve of mice
transgenic for human mutant P301S tau. Transport was examined using cholera toxin B tracing. Retrograde transport was
reduced in transgenic mice at 3 and 5 months of age, when compared to C57/Bl6 control mice. Anterograde axonal
transport was also reduced in 3-month-old transgenic mice. Mild excitotoxic injury of retinal ganglion cells resulted in
greater nerve cell loss in retinas from 3- and 5-month old P301S transgenic mice, when compared to controls. In conjunction
with the detection of abnormal tau in the optic nerve in human and experimental glaucoma, the present findings suggest
that tau hyperphosphorylation and aggregation may constitute targets for neuroprotective therapies in glaucoma as well as
tauopathies.
Citation: Bull ND, Guidi A, Goedert M, Martin KR, Spillantini MG (2012) Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in
Mice Transgenic for Human Mutant P301S Tau. PLoS ONE 7(4): e34724. doi:10.1371/journal.pone.0034724
Editor: Ju ¨rgen Go ¨tz, The University of Sydney, Australia
Received August 23, 2011; Accepted March 8, 2012; Published April 4, 2012
Copyright:  2012 Bull et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Fight for Sight United Kingdom; Cambridge University Hospitals’ National Health Services Foundation Trust (Addenbrooke’s Hospital); the Glaucoma
Foundation; Medical Research Council; National Institute for Health Research; Addenbrooke’s Research Trust; Alzheimer’s Research United Kingdom. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mgs11@cam.ac.uk (MGS); krgm2@cam.ac.uk (KRM)
Introduction
Microtubule-associated protein tau is believed to play a role in the
assembly and stabilisation of microtubules [1]. Its binding to
microtubules is negatively regulated by phosphorylation. In several
neurodegenerative diseases, tau protein assembles into abnormal
filaments, where it is abnormally hyperphosphorylated. The identi-
fication of MAPT mutations in inherited frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17T) has established
that dysfunction of tau protein is sufficient to cause neurodegeneration
and dementia [2–4]. Most mutations are located in or near the repeat
region of tau, which is essential for microtubule binding. Conse-
quently, mutant tau has been shown to exhibit reduced microtubule
binding [5,6], suggesting that a partial loss of function may be required
for filament assembly and abnormal hyperphosphorylation. In
addition, many MAPT missense mutationsalso increase the propensity
of tau protein to assemble into filaments [7,8].
Transgenic models expressing human mutant tau in nerve cells
havebeen useful for investigating the toxicity of tau aggregationand
how dysfunctional tau interferes with axonal transport. Defective
axonal transport, both anterograde and retrograde, has been
described in some of these models [9,10]. We previously showed
that inretinal ganglioncells from a mouse line transgenicfor human
mutant P301S tau, dynactin, which is required for the binding of
cargo to dynein motor proteins, is abnormally distributed [11]. We
also showed that recombinant human tau promotes attachment of
the dynactin complex to axonal microtubules, indicating a potential
role for tau in axonal transport. Dynein-mediatedretrogradeaxonal
transport of target-derived neurotrophic factors, such as brain-
derived neurotrophic factor (BDNF), is essential for the survival of
adult retinal ganglion cells (RGCs) [12]. Disruption of BDNF
transport contributes to retinal ganglion cell death in glaucoma
[13,14] where, in an experimental model, we have previously
described an altered distribution of dynein [15].
Here we examined the effects of human mutant P301S tau
expression in retinal ganglion cells on axonal transport and nerve
cell survival in vivo. In this transgenic line, human mutant P301S
tau is expressed downstream of the murine Thy1 promoter [16].
By 5 months of age, homozygous mice exhibit widespread tau
aggregation and neurodegeneration, accompanied by behavioural
impairment and motor dysfunction. We previously described the
presence of aggregated human mutant tau in RGCs of these mice
[17]. However, nerve cell loss was not observed and retrograde
axonal transport in retinal explant cultures appeared to be normal.
We now show that aggregation of human mutant P301S tau in
RGCs is associated with a reduction of both anterograde and
retrograde axonal transport in vivo, and with a markedly increased
effect of mild excitotoxic injury.
Materials and Methods
Ethics statement
Animals had unrestricted access to food and water, and were
maintained on a 12 h light/dark cycle. All experiments were
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34724carried out in accordance with the UK Home Office Regulations
for the Care and Use of Laboratory Animals and the UK Animals
(Scientific Procedures) Act 1986. All methods were approved by
the University of Cambridge Animal Ethics Committee (project
licences 80/1914 and 80/2360).
Animals
Homozygous male mice transgenic for human mutant P301S
tau were used at 1, 3 and 5 months of age. At 5 months, these mice
exhibit abnormal motor behaviour. No such abnormality is
present in animals aged 3 months or 1 month. Filamentous
inclusions made of hyperphosphorylated tau are present in the
central nervous system of 3- and 5-month old transgenic mice
[18]. We previously described the expression of human mutant
P301S tau in RGCs and the formation of tau inclusions [17].
Based on staining with the fluorescent Congo red derivative FSB
[19], the first filamentous tau aggregates in RGCs were observed
in 7-week old mice. Age- and sex-matched C57/Bl6 mice (Harlan,
UK) were used as controls. Animals had unrestricted access to
food and water, and were maintained on a 12 h light/dark cycle.
All experiments were carried out in accordance with the UK
Home Office Regulations for the Care and Use of Laboratory
Animals and the UK Animals (Scientific Procedures) Act 1986.
They were approved by the University of Cambridge Animal
Ethics Committee (project licence 80/1914).
Tracing of anterograde axonal transport
Mice aged 1 month (P301S, n=6; C57/Bl6, n=6), 3 months
(P301S, n=5; C57/Bl6, n=5) and 5 months (P301S, n=6; C57/
Bl6, n=4) were used. The vitreous body of the left eye was
injected with 2 ml of a 0.1% solution of cholera toxin B protein
(CTB) conjugated to Alexa Fluor-555 in sterile phosphate-buffered
saline (PBS) (Invitrogen Inc., Paisley, UK). Following the injection,
the needle was held in place for 30 s, to prevent leakage. Mice
were perfused intracardially 1 day after the injection.
Tracing of retrograde axonal transport
Mice aged 3 months (P301S, n=6; C57/Bl6, n=6) and 5
months (P301S, n=10; C57/Bl6, n=4) were used. They were
fixed in a stereotaxic frame (World Precision Instruments Ltd.,
Stevenage, UK), an incision was made through the scalp to expose
the skull and Bregma identified as the zero point. One mlo fa1 %
solution of CTB conjugated to Alexa Fluor-555 was injected
bilaterally into the superior colliculus (coordinates: anterior-
posterior 22.92 mm and medio-lateral 60.5 mm from Bregma;
dorso-ventral 22 mm from the surface of the skull). Injections
were performed over 2 min and the needle left in place for 1
additional min. Mice were perfused intracardially 3 days after the
injection.
Excitotoxic lesioning in vivo
Mice aged 1 month (P301S, n=4; C57/Bl6, n=4), 3 months
(P301S, n=6; C57/Bl6, n=4), and 5 months (P301S, n=7; C57/
Bl6 n=6) were used. One ml of 2 mM NMDA (N-methyl-D-
aspartate; Sigma-Aldrich UK, Gillingham, UK) and 5 mM
glycine (Sigma-Aldrich UK) in PBS was injected into the vitreous
body of the left eye. The needle was held in place for 30 s
following injection, to prevent leakage. This resulted in a
concentration of 2 nmol NMDA and 5 nmol glycine per eye,
which caused a mild excitotoxic injury of the retina [20]. Mice
were perfused intracardially after 7 days.
Quantification of retinal ganglion cells
The retinas of perfused mice were dissected and four radial cuts
made in each retina, to facilitate whole mount staining and
analysis. This was followed by a 2 h post-fixation in 4%
paraformaldehyde/0.1 M PBS. The retinas were washed in
PBS, followed by a 60 min incubation in blocking solution
consisting of 0.2% Triton-X100 (Sigma-Aldrich UK) and 5% goat
serum (Invitrogen Inc.) in PBS. They were then incubated for 24 h
at 4uC with monoclonal anti-NeuN antibody (1:500, Millipore,
Watford, UK) in blocking solution, followed by washing in PBS.
The retinas were incubated for 18 h at 4uC with Alexa Fluor-555
conjugated goat anti-mouse antibody (1:1,000, Invitrogen Inc.) in
blocking buffer. Following washing in PBS, the tissues were
mounted on glass slides. Analyses were carried out blind with
respect to treatment groups. The RGC layer was viewed under
epifluorescent illumination and three images (central, medial and
peripheral) per retinal quadrant captured using a 406 objective
(Figure 1A). Each image sampled an area of 0.093 mm
2; thus, with
12 images per retina (1.116 mm
2), and given an explant area of
15.7660.31 mm
2, approximately 7% of the flat mount area of the
retina was sampled. NeuN-positive cells were counted and the
number of RGCs determined. The percentage loss of RGCs
following excitotoxin administration was calculated by comparing
the treated and untreated eyes.
Excitotoxic lesioning in vitro
Retinas from mice aged 5 months (P301S, n=4 mice; C57/Bl6,
n=4 mice; both retinas from each mouse were pooled) were
dissociated into single cell suspensions using a papain dissociation
system (Worthington Corporation, Lakewood, NJ, USA), follow-
ing the manufacturer’s instructions. The cells were plated at a
density of 4610
5 cells/well (24-well plates) on poly-L-lysine
Figure 1. Quantification Methodology. (A), Retinal ganglion cell
(RGC) survival following excitotoxic injury in vivo was quantified using
retinal flat mounts immunohistochemically labelled for NeuN. Twelve
images (3 per quadrant at central, medial and peripheral locations;
approximate positions defined by boxes) were captured per retina
using a 406 objective; NeuN-positive nuclei were counted in each
image and their average number calculated for each retina. RGC loss
was calculated compared to NeuN counts from the uninjured
contralateral eye. (B), Axonal transport of fluorescent cholera toxin B
(CTB) in the optic nerve was quantified by measuring average
fluorescence intensity across the width of the optic nerve at 100 mm
intervals along the full length of each nerve. A representative image is
shown, with the white lines indicating example regions where average
fluorescence intensity was measured. Scale bar, 100 mm.
doi:10.1371/journal.pone.0034724.g001
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Aldrich UK) coated glass coverslips in control medium (to make
25 ml: 24.2 ml Neurobasal-A medium, 500 ml B27 supplement,
62.5 ml L-glutamine, 125 ml gentamicin; all from Invitrogen Inc.)
or in pH-balanced medium containing 100 mM glutamic acid
(Sigma-Aldrich UK). After 3 days, the cells were fixed with 4%
paraformaldehyde/0.1 M PBS and labelled with an anti-bIII
tubulin antibody (1:2000, Promega, Southampton, UK). The
number of labelled cells in 10 fields of view per coverslip (4
replicate coverslips per N), using a 206 objective, was counted,
and averaged over 4 coverslips for each sample. Cells were
counted and the percentage of surviving cells determined by
comparing cell counts between glutamate-treated and untreated
control groups. An unpaired Student’s t-test was used to compare
retinal ganglion cell survival between P301S and C57/Bl6
cultures; a p value of less than 0.05 was considered significant.
CTB binding to GM1 ganglioside receptor in retina and
brain tissue
Sections of fixed retina (14 mm) and superior colliculus (30 mm)
were obtained from 3 month old P301S and C57/Bl6 mice.
Retinal sections were immunohistochemically labelled with a
mouse monoclonal anti-bIII tubulin antibody (1:2000; Promega
UK, Southampton, UK), and brain sections immunohistochem-
ically labelled with a mouse monoclonal anti-vGluT2 antibody
(Abcam Plc, Cambridge, UK). An Alexa Fluor-488 conjugated
goat anti-mouse secondary antibody (1:1000, Invitrogen Inc.) was
used to detect the primary antibody, and sections were exposed to
Alexa Fluor-555 conjugated CTB protein (5 mg/ml; Invitrogen
Inc) to visualise GM1 receptor binding. The retinal sections were
imaged using laser scanning confocal microscopy (TCS-SPE,
Leica Inc., Wetzlar, Germany), and brain sections were imaged
using epifluorescent microscopy (DM6000 microscope; Leica Inc.).
Quantification of the axonal transport of cholera toxin B
Optic nerves of perfused micewere dissected between the posterior
globe and the optic chiasm, post-fixed overnight at 4uC, washed in
PBS and cryo-preserved by overnight immersion in 30% sucrose at
4uC. Following embedding in OCT, 14 mm-thick longitudinal
sections were cut using a cryostat and mounted onto microscope
slides. They were immunohistochemically labelled for bIII tubulin
(1:2000, Promega), immunohistochemical visualisation of CTB was
not required as the fluorophore was directly conjugated to the CTB
protein. Analyses were carried out blind with respect to treatment
groups. Optic nerve sections were visualised under epifluorescent
illumination on a single Leica DM6000 microscope using a 106
objective and contiguous images along the length of each nerve
captured using LAS AF software (Leica Inc.) and identical camera
settings. Mean fluorescence intensity was measured across the width
of each nerve at 100 mm intervals along its length (Figure 1B) and
plotted as a line graph against distance (along the nerve), and the area
under the curve (AUC) calculated using Prism software (GraphPad,
La Jolla, USA). The AUC values were averaged across each
experimental group and an unpaired Student’s t-test used for
statistical comparison of CTB transport; p,0.05 was considered
significant. Fluorescence intensity was also measured along the length
of a single optic nerve from an untreated right eye in each
Figure 2. Expression of human tau in the optic nerve of mice
transgenic for human mutant P301S tau. (A–C), Staining for
human tau (A, green) and bIII tubulin (B, red) showed co-localisation in
the axons of the optic nerve (C, overlay image of A and B; example from
1 month old mouse). (D–F), Staining for tau phosphorylated at S202/
T205 (D, green) and bIII tubulin (E, red) showed co-localisation in the
axons of the optic nerve (F, overlay image of D and E; example from 5
month old mouse). Arrows indicate examples of co-localisation. Scale
bar, 20 mm.
doi:10.1371/journal.pone.0034724.g002
Figure 3. Binding of cholera toxin B (CTB) protein to GM1
receptor in P301S tissue. Fixed retinal (A–B) and brain (C–F) tissue
was exposed to fluorescently tagged CTB (red) in order to visualise GM1
receptor binding in both C57/Bl6 control tissue (A, C–D) and P301S
tissue (B, E–F). CTB binding was observed in RGCs within the retina (A–
B), counterstained for the marker bIII tubulin (green; arrows indicate co-
localisation), and punctate staining within the inner retina was also
seen. Nuclei were counterstained with DAPI (blue). No difference in the
pattern of CTB binding to the GM1 receptor in the retina was found
between control (A) and P301S (B) tissue. Furthermore, no difference in
the pattern of CTB binding to the GM1 receptor in the superior
colliculus (outlined) of the brain was observed between control (D) and
P301S (F) tissue. The RGC axon terminals in the superior colliculus were
counterstained for the marker vGluT2 (vesicular glutamate transporter
2; green) in both control (C) and P301S (E) tissue. Scale bar, 25 mm A–B,
500 mm C–F.
doi:10.1371/journal.pone.0034724.g003
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34724Figure 4. Anterograde axonal transport is reduced in optic nerve of mice transgenic for human mutant P301S tau mice. Fluorescent
cholera toxin B was injected unilaterally into the vitreous and the amount transported in an anterograde direction measured in 5-month-old (A), 3-
month-old (C) and 1-month-old (E) P301S tau transgenic and C57/Bl6 control mice. Fluorescence intensity appeared lower in transgenic mice at all
ages, compared to controls. In optic nerves not exposed to cholera toxin B (negative control), only background fluorescence was measured (A,C,E).
Statistical analysis of the area under the fluorescence intensity curve for each individual showed a significant reduction of anterograde axonal
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cence was well below that detected in CTB-treated optic nerves.
Tau immunohistochemistry
Optic nerve sections were immunohistochemically double-
labelled with a rabbit polyclonal anti-bIII tubulin antibody
(1:1000; Covance, Harrogate, UK), and either mouse monoclonal
antibody HT7 (1:500; Pierce Protein Research Products, Thermo
Fisher Scientific, Cramlington, UK) or phosphorylation-depen-
dent mouse monoclonal anti-tau antibody AT8 (1:1000; Source
Bioscience Autogen, Calne, UK). The secondary antibodies were
Alexa Fluor-647 conjugated goat anti-rabbit antibody (1:1000,
Invitrogen Inc.) and Alexa Fluor-488 conjugated goat anti-mouse
antibody (1:1000, Invitrogen Inc.). The sections were imaged using
laser scanning confocal microscopy (TCS-SPE, Leica Inc.).
Results
Expression of hyperphosphorylated human mutant
P301S tau in optic nerve
We have shown previously that the P301S tau transgene is
expressed by retinal ganglion cells (RGCs), under the Thy1
promotor, within the inner retina and nerve fibre layer [17].
Furthermore, it was demonstrated that expression of this transgene
transport in optic nerves from P301S tau transgenic mice at 5 months (B) and at 3 months (D), but not at 1 month (F). Data are presented as
mean6SEM.
doi:10.1371/journal.pone.0034724.g004
Figure 5. Retrograde axonal transport is reduced in optic nerve of mice transgenic for human mutant P301S tau. Fluorescent cholera
toxin B was injected bilaterally into the superior colliculus and the amount transported measured in 5-month-old (A) and 3-month-old (C) P301S tau
transgenic and C57/Bl6 control mice. Fluorescence intensity was lower along the length of the optic nerve in transgenic mice at all ages, compared to
C57/Bl6 controls. Statistical analysis of the area under the fluorescence intensity curve for each individual showed a significant reduction in retrograde
axonal transport in optic nerves from P301S tau transgenic mice at 5 months (B) and at 3 months (D), compared to controls. Data are presented as
mean6SEM.
doi:10.1371/journal.pone.0034724.g005
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tau within RGC axons in the retina of these mice by the age of 2
months. In the current project, we extended these findings by
probing the relevance of RGC axonal expression of mutant
human tau in the optic nerve of P301S tau transgenic mice. We
confirmed human tau was present in axons of retinal ganglion
cells, as reflected by the co-labelling with antibodies HT7 (human
tau specific antibody) and bIII tubulin (RGC marker; Figure 2A–
C) in the optic nerve from at least 1 month of age. Double-
labelling with anti-tau antibody AT8 and the anti-bIII-tubulin
antibody established the presence of abundant hyperphosphory-
lated tau in RGC axons at both 3 and 5 months of age (Figure 2D–
F), while the AT8 staining was lower at 1 month of age, consistent
with our earlier study.
Binding of cholera toxin B (CTB) protein to GM1 receptor
in P301S tissue
Anterograde and retrograde transport of cholera toxin B (CTB)
protein was used as a tool to assess RGC axonal transport. Binding
of CTB to its receptor, the GM1 ganglioside receptor, on RGCs in
both the retina and brain was examined to determine whether
differences in receptor expression were apparent between P301S
transgenics and controls. No difference in CTB binding to RGC
somas, counterstained for the marker bIII tubulin (Figure 3A, B),
or RGC terminals, counterstained for vGluT2 expression
(Figure 3C–F), was observed between P301S and control tissue.
Reduction of anterograde axonal transport in optic nerve
from human mutant P301S tau transgenic mice
Fluorescently tagged CTB was administered intravitreally and
anterograde axonal transport in the optic nerve investigated 24 h
later. Transgenic mice aged 5 months, 3 months and 1 month
were used. Measurement of CTB fluorescence intensity showed
that anterograde axonal transport was significantly impaired in
transgenic animals aged 5 months (Figure 4A,B) and 3 months
(Figure 4C,D), compared to controls. No significant impairment
was detected in transgenic mice at 1 month of age (Figure 4E,F).
The average fluorescence intensity along the untreated optic nerve
showed that all experimental measurements were above back-
ground (Figure 4A,C,E).
Reduction of retrograde axonal transport in optic nerve
from human mutant P301S tau transgenic mice
Fluorescently tagged CTB was injected into the superior
colliculus and retrograde axonal transport in the optic nerve
investigated 72 h later. Transgenic mice aged 5 months and 3
months were used; 1 month old animals were not used as their
small size prevented accurate injection into the superior colliculus.
Measurement of CTB fluorescence intensity showed that retro-
grade axonal transport was significantly impaired in transgenic
mice aged 5 months (Figure 5A,B) and 3 months (Figure 5C,D),
compared to controls.
Increased susceptibility to excitotoxic injury of mice
transgenic for human mutant P301S tau
To investigate the sensitivity of RGCs to injury, we exposed the
retinas of wild-type and transgenic mice to a mild excitotoxic
injury via intravitreal injection of 2 nmol NMDA plus 5 nmol
glycine, as described [20]. One week after injection, the number of
RGCs was reduced in the retinas of both human mutant P301S
tau transgenic and C57/Bl6 control mice at 1, 3 and 5 months of
age (Figure 6), however, while no difference in RGC loss was
observed between 1 month old transgenic and control mice,
significantly more RGCs died after mild excitotoxic injury in
transgenic compared to control retinas at both 3 and 5 months of
age (Figure 6E). In contrast, RGCs cultured from dissociated 5
month old P301S retinas, which disconnects them from their
dependence upon retrograde neurotrophic supply, were no more
susceptible to glutamate-induced death compared to RGCs
isolated from C57/Bl6 retinas (percentage survival bIII tubulin
+
cells in toxin-treated cultures compared to untreated cultures:
P301S 76.2264.83% compared to C57/Bl6 63.0362.65%,
mean6SEM, p.0.05, n=4).
Discussion
Hyperphosphorylation and aggregation of tau were associated in
vivo with reduced axonal transport, both anterograde and
retrograde, in the optic nerve of mice from a line transgenic for
human mutant P301S tau. Axonal transport was assessed by
Figure 6. Reduced axonal transport in optic nerve of mice
transgenic for human mutant P301S tau increases neuronal
susceptibility to injury. Retinal ganglion cell (RGC) survival was
quantified following a mild unilateral excitotoxic injury of the left eye
(LE) by counting NeuN-positive nuclei in the RGC layer of the whole-
mounted retina of 1, 3 and 5 month old mice (A–D). Percentage RGC
loss was calculated by comparing the number of surviving RGCs in
injured retinas to that of the uninjured right eye (RE). Representative
images of NeuN-positive nuclei in injured P301S tau transgenic (A) and
C57/Bl6 (C) retinas from 5 month old animals, compared to uninjured
contralateral retinas (B and D), are shown as an example. Statistical
analysis revealed a significant increase in RGC death following mild
excitotoxic injury in P301S tau transgenic retinas, compared to C57/Bl6
control retinas (E), at both 3 months and 5 months of age; however no
difference in RGC excitotoxic death was found at 1 month of age
between control and transgenic retinas. N-methyl-D-aspartic acid
(NMDA) was used as the excitotoxin. Scale bar, 100 mm.
doi:10.1371/journal.pone.0034724.g006
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CTB. Impairment of axonal transport in transgenic P301S tau
mice impacted negatively on the ability of RGCs to withstand a
mild excitotoxic injury, resulting in enhanced nerve cell death. In
comparison, when RGCs were dissociated and cultured in vitro,
where cell survival was disassociated from reliance upon axonal
transport, no difference in RGC survival was observed. In previous
work in retinal explants of P301S tau transgenic mice [17], we
failed to detect a reduction in retrograde axonal transport, possibly
because this work was done in retinal explants where RGCs are
axotomised.
In normal brain, the binding of tau to microtubules could
regulate axonal transport. Tau has been reported to interfere with
the binding of motor proteins to microtubules [21] and a tau
gradient along the axon has been described, with the highest levels
close to the synapse [22]. However, the effects of ablation of tau
and increased tau expression on axonal transport have demon-
strated that the rates of slow and fast transport along optic nerve
axons in vivo are not significantly affected by the modulation of tau
levels [23]. In squid axoplasm, where it was only weakly
phosphorylated , monomeric tau did not affect axonal transport,
even when present at 20-times its normal level [24]. Furthermore,
the rates of axonal transport of human wild-type and mutant tau
were similar in cultured cortical neurons [25]. It follows that the
reduction of axonal transport described here was probably not due
to the overexpression of monomeric human mutant tau, but
resulted from tau hyperphosphorylation and aggregation. A
similar conclusion was reached in studies of axonal transport in
ventral roots of mice transgenic for tau with mutation R406W [9]
and in dopaminergic substantia nigra neurons of mice transgenic
for tau with mutation K369I [10]. Physiological phosphorylation
of tau, as such, is probably not detrimental, since it occurs
normally during foetal development [26] and hibernation [27].
However, the pathological hyperphosphorylation characteristic of
human neurodegenerative diseases differs from that observed in
foetal brain and during hibernation and may result in some toxic
effects [1]. In support, overexpression of wild-type human tau in
mouse neurons leads to some tau and impairment of axonal
transport, in the absence of tau filament formation and significant
neurodegeneration [28–30]. Aggregation of tau, in contrast, is
likely to cause more extensive toxicity [1]. This is consistent with
our finding that axonal transport was not impaired in 1 month old
transgenic mice (Figure 4E, F), where less soluble tau was stained
by the AT8 phosphorylation dependent anti-tau antibody in the
RGC axons [17]. Impairment of axonal transport may result from
the space-occupying nature of tau aggregates. In addition, more
specific mechanisms may also be at work. We have previously
shown that in the mouse line transgenic for human mutant P301S
tau the dynactin complex is redistributed and exhibits a reduced
interaction with microtubules [11]. It has also been reported that
filamentous tau inhibits anterograde axonal transport by activating
protein phosphatase 1 and glycogen synthase kinase-3, following
increased exposure of amino acids 2–18 of tau, which comprise a
phosphatase-activating domain [31,32].
Reduced axonal transport may contribute to neurodegeneration
by putting nerve cells under stress, limiting their ability to
withstand injury. Thus, a mild excitotoxic insult, which kills fewer
than 20% of RGCs in 3–5 month old control mice, killed 40–50%
of RGCs in age-matched human P301S tau mice. Hyperexcit-
ability of vulnerable nerve cells has been described as an early
change along the path to neurodegeneration in many experimen-
tal animal models [33]. When survival was uncoupled from
retrograde neurotrophic support by culturing dissociated RGCs in
vitro (see Results for data values), or when axonal transport was not
differentially affected (as in 1 month old animals; Figure 6E),
excitotoxic injury equally affected the survival of wild-type and
transgenic RGCs.
Impairment of axonal transport may be particularly deleterious
for neurons such as RGCs, which rely heavily on retrograde
trophic support. Interruption of retrograde axonal transport of
target-derived BDNF and its receptor TrkB has been shown to
contribute to the loss of RGCs in glaucoma [13,14]. Pathological
tau species have been detected in glaucoma [34], raising the
possibility that dysfunction of tau may also be relevant in this
disease.
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